AVX 012

Drug Profile

AVX 012

Alternative Names: AVX-012

Latest Information Update: 18 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Instituto de Neurociencias de Alicante
  • Developer AVX Pharma
  • Class Eye disorder therapies; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Dry eyes

Most Recent Events

  • 13 Jul 2017 Phase-II clinical trials in Dry eyes in Spain (Ophthalmic)
  • 01 Jul 2016 Avizorex Pharma files an clinical trial application with the Spanish Competent Authority in Spain for Dry eye syndrome
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top